Replies to post #2467 on Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

The "Poziotinib Efficacy in EGFR Cohort"' slide 12/ p. 12, in the Jan 2019 Presentation

http://investor.sppirx.com/index.php/static-files/202ee8f6-aecf-4ab5-9bbf-91af8de17c28

where

DOR for Confirmed Responders (months) (event/censor) 12 (7/5) 6.6
and
Progression-free Survival (months) (event/censor) 30 (18/12) 6.5

These pts they lost track of may have evented or Lost to Follow-up (LTFU) (LTFU count as censored too) and count when determining a KM curve. And in this trial, they are not looking at KM curves but still when you have 12 out of 30 pts where you don't have final data, perhaps the agency felt that was inadequate. TTB, I'm just musing to myself and trying to figure out why BTD wasn't granted. I just can't accept that a almost doubling of ORR didn't make the grade no matter how many ways you slice it. Anyhows, have a good weekend.